Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.

Alzheimer's research & therapy - 27 Dec 2019

Lin Szu-Ying, Lin Kun-Ju, Lin Po-Chen, Huang Chin-Chang, Chang Chiung-Chih, Lee Yi-Chung, Hsiao Ing-Tsung, Yen Tzu-Chen, Huang Wen-Sheng, Yang Bang-Hung, Wang Pei-Ning

Abstract excerpt

INTRODUCTION: Due to the high cost and high failure rate of ascertaining amyloid positron emission tomography positivity (PET+) in patients with earlier stage Alzheimer's disease (AD), an effective pre-screening tool for amyloid PET scans is needed. METHODS: Patients with mild cognitive impairment (n = 33, 24.2% PET+, 42% females, age 74.4 ± 7.5, MMSE 26.8 ± 1.9) and mild dementia (n = 19, 63.6% PET+, 36.3%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins E

Share to Cognitive Dysfunction

Share to Peptide Fragments

Share to Positron-Emission Tomography

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 31881963
DOI: 10.1186/s13195-019-0566-0
PMCID: PMC6933740

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.PMID 31881963Read ↗

Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity Read ↗

Definition of a threshold on the plasma Aβ42/Aβ40 ratio measured by single-molecule array to predict the amyloid status of individuals without dementiaSemantic proximity Read ↗

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.Semantic proximity Read ↗

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Semantic proximity Read ↗

Risk Factors Predicting Amyloid PET Positivity in Patients with Mild Cognitive Impairment and Apolipoprotein E ɛ3/ɛ3 Genotypes.Semantic proximity Read ↗

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Semantic proximity Read ↗

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's diseaseSemantic proximity Read ↗

APOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.Semantic proximity Read ↗

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read ↗

Performance of Plasma Amyloid β, Total Tau and Neurofilament Light Chain Levels for Alzheimer’s Disease IdentificationSemantic proximity Read ↗

Assessment of apolipoprotein E genotype for β-amyloid status prediction.Semantic proximity Read ↗

Predicting Amyloid Pathology in Mild Cognitive Impairment Using Radiomics Analysis of Magnetic Resonance ImagingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.